Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Poteligeo (mogamulizumab-kpkc)
i
Other names:
KM8761, KW 0761, AMG 761, KW-0761
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(9)
News
Trials
Company:
Kyowa Kirin
Drug class:
CCR4 receptor antagonist
Related drugs:
‹
FLX475 (5)
FLX475 (5)
›
Associations
(9)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
mogamulizumab-kpkc
Sensitive: A2 - Guideline
mogamulizumab-kpkc
Sensitive
:
A2
mogamulizumab-kpkc
Sensitive: A2 - Guideline
mogamulizumab-kpkc
Sensitive
:
A2
CCR4 positive
Leukemia
CCR4 positive
Leukemia
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
CCR4 positive
Lymphoma
CCR4 positive
Lymphoma
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
CCR4 negative
Solid Tumor
CCR4 negative
Solid Tumor
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
HGF-L
T Acute Lymphoblastic Leukemia
HGF-L
T Acute Lymphoblastic Leukemia
mogamulizumab-kpkc
Resistant: C3 – Early Trials
mogamulizumab-kpkc
Resistant
:
C3
mogamulizumab-kpkc
Resistant: C3 – Early Trials
mogamulizumab-kpkc
Resistant
:
C3
CD28 overexpression
Lymphoma
CD28 overexpression
Lymphoma
mogamulizumab-kpkc
Resistant: C3 – Early Trials
mogamulizumab-kpkc
Resistant
:
C3
mogamulizumab-kpkc
Resistant: C3 – Early Trials
mogamulizumab-kpkc
Resistant
:
C3
CD28 overexpression
Leukemia
CD28 overexpression
Leukemia
mogamulizumab-kpkc
Resistant: C3 – Early Trials
mogamulizumab-kpkc
Resistant
:
C3
mogamulizumab-kpkc
Resistant: C3 – Early Trials
mogamulizumab-kpkc
Resistant
:
C3
CCR4 negative
Esophageal Cancer
CCR4 negative
Esophageal Cancer
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
CCR4 negative
Lung Cancer
CCR4 negative
Lung Cancer
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login